Revolution Medicines, Inc. (RVMD)

Revolution Medicines' stock has experienced positive momentum, with a 49.11% price return over the past six months. This is due to positive analyst sentiment, a strong Q3 2025 earnings report, and clinical and regulatory milestones. The company reported a wider net loss of $305.2 million in Q3 2025, driven by higher operating expenses. CEO Mark Goldsmith sold 30,000 shares of common stock on November 7, 2025.

There is no information available regarding demand seasonality for Revolution Medicines, Inc.'s products and services. Demand is primarily driven by clinical trial progress, regulatory approvals, and the prevalence of RAS-addicted cancers.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on discovering and developing targeted therapies for RAS-addicted cancers. The company's pipeline includes RAS(ON) inhibitors like Daraxonrasib, Elironrasib G12C, and Zoldonrasib G12D, as well as RAS companion inhibitors such as RMC-4630, RMC-5552, and RMC-5845.

Revolution Medicines is headquartered in Redwood City, California, with additional offices in Cambridge, Massachusetts, and operates through subsidiaries in the US and the UK. The company conducts clinical trials across North America, Europe, and Asia-Pacific.

No specific information regarding Revolution Medicines, Inc.'s brand reputation was found in the provided search results. The available information primarily focuses on financial performance, clinical trial progress, and stock market activity.

Institutional investors hold a significant portion of Revolution Medicines' stock, ranging from 76.44% to 88.74%. Major institutional owners include Vanguard Group Inc, Farallon Capital Management Llc, and Janus Henderson Group Plc. Individual and insider ownership ranges from approximately 6.19% to 10.61%, with Thilo Schroeder owning 8.09 million shares.